[T.S.R:17548] Shasun Pharma To Invest Rs 100 cr Into A New Facility At Visakhapatnam

Shasun Pharmaceuticals expects to set up its long overdue plant in Visakhapatnam this year. The delay was due to the time taken for "identification of the right product mix", but now Shasun is ready to go ahead. The company will invest Rs 100 crore in the plant that will manufacture active pharmaceutical ingredients (API), but the investment will be spread over two years.  

In the current year, Shasun will spend Rs 20 crore on the plant, Mr Abhaya Kumar, Managing Director, Shasun Pharmaceuticals, told

Business Line today. Mr Kumar, a member of the promoter-family who took over as the Managing Director on April 1, plans to cleave the company into strategic business units — API, formulations, contract manufacturing, biotech and nanotechnology.

 

Japan FTA

 

Shasun expects $15-20 million (about Rs 90 crore) revenue from Japan and the neighbouring markets such as Korea and China in the next two years. Mr Kumar said the Free Trade Agreement signed by Japan and India has helped the pharmaceutical industry. The Japanese are now open to accepting generics from India to reduce the cost of their healthcare.

 

The other advantage in Japan would be having strategic buyers for the long term (say 10 years), while in other countries it may be for smaller periods, he said. Shasun has an office in Japan that is headed by a Japanese; the office caters to markets such as Korea and China.

 

Safe Harbor Statement:

Some forward looking statements on projections, estimates, expectations & outlook are included to enable a better comprehension of the Company prospects. Actual results may, however, differ materially from those stated on account of factors such as changes in government regulations, tax regimes, economic developments within India and the countries within which the Company conducts its business, exchange rate and interest rate movements, impact of competing products and their pricing, product demand and supply constraints.

 

Nothing in this article is, or should be construed as, investment advice.

 

 

 

 

 

--
For Anything related with Stock market be Online at
http://www.niftyviews.com/
 
Get free updates on your mobile phone. Sms "Join TSR " and send to 09223492234
 
FOR TRIAL STOCK/NIFTY/OPTION CALLS
 
 
You received this message because you are subscribed to Google Group "STOCKRESEARCHER" group.
To post to this group, send an email to STOCKRESEARCHER@googlegroups.com
 
To unsubscribe email
Stockresearcher-unsubscribe@googlegroups.com
 
for more info visit
http://groups.google.com/group/STOCKRESEARCHER?hl=en-GB
.
This is Not a Spam Mail.
Disclaimer :-
"The opinions expressed by the members on this board are based on
their individual experience and perceptions and to share information
with other members with the best of intentions to help fellow members
in investment decisions as equity investment is a risky venture."